Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4372672 | 0.97 | TUBB1 (0.44) | TUBB1CYP3A4CYP2C9PKMCYP2C19 | |
| SCHEMBL4365733 | 0.96 | TUBB1 (0.48) | TUBB1CYP3A4CYP2C9PKMCYP2C19 | |
| SCHEMBL4366643 | 0.95 | TUBB1 (0.51) | TUBB1CYP3A4CYP2C9PKMCYP2C19 | |
| SCHEMBL4366652 | 0.95 | TUBB1 (0.51) | TUBB1CYP3A4CYP2C9PKMCYP2C19 | |
| SCHEMBL4368768 | 0.94 | TUBB1 (0.48) | TUBB1CYP3A4CYP2C9PKMCYP2C19 | |
| SCHEMBL4374039 | 0.88 | TUBB1 (0.48) | TUBB1 | |
| SCHEMBL4371716 | 0.88 | TUBB1 (0.54) | TUBB1GAAALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL4372676 | 0.85 | TUBB1 (0.45) | TUBB1TACR1 | |
| SCHEMBL4364705 | 0.85 | TUBB1 (0.54) | TUBB1CYP3A4CYP2C9CYP2C19GAA | |
| Trifluoroacetic Acid SCHEMBL4852391 | 0.85 | TUBB1 (0.51) | TUBB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7626023-B2 | Compounds for treating tumors | WYETH (US) | 2009-12-01 | — | — | US | disclosed |
| US-20080221181-A1 | COMPOUNDS FOR TREATING TUMORS | WYETH HOLDINGS CORPORATION (US) | 2008-09-11 | — | — | US | disclosed |
| US-7390910-B2 | Compounds for treating tumors | WYETH (US) | 2008-06-24 | — | — | US | disclosed |
| WO-2005016958-A2 | COMPOUNDS FOR TREATING TUMORS | WYETH HOLDINGS CORPORATION (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20050037977-A1 | Compounds for treating tumors | WYETH HOLDINGS CORPORATION (US) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221181-A1 | COMPOUNDS FOR TREATING TUMORS | RB1, MRPL9, BCOR | TUBB1 588/4885CYP3A4 3441/4885CYP2C9 1243/4885 |
| US-20050037977-A1 | Compounds for treating tumors | RB1, MRPL9, BCOR | TUBB1 588/4885CYP3A4 3441/4885CYP2C9 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.